Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer

Krebs, Matthew; Renehan, Andrew G; Backen, Alison; Gollins, Simon; Chau, Ian; Hasan, Jurjees; Valle, Juan W; Morris, Karen; Beech, Janette; Ashcroft, Linda; Saunders, Mark; Dive, Caroline

doi:10.1016/j.clcc.2014.12.006

Cited by 47 publications

(37 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monitoring of treatment responses is one of the key applications of CTC assays (19)(20)(21). In the present study, we observed significant correlation between changes in CTC counts and response to therapy.…”

Section: Discussionsupporting

confidence: 68%

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells

Gorges

Penkalla²,

Schalk³

et al. 2016

Clinical Cancer Research

138

136

View full text Add to dashboard Cite

Purpose: The use of circulating tumor cells (CTC) as "liquid biopsy" is limited by the very low yield of CTCs available for subsequent analyses. Most in vitro approaches rely on small sample volumes (5-10 mL).Experimental Design: Here, we used a novel approach, the GILUPI CellCollector, which enables an in vivo isolation of CTCs from peripheral blood. In total, 50 lung cancer patients were screened in two subsequent device applications before and after therapy (n ¼ 185 applications).Results: By in vivo isolation, 58% (108/185) of the patients were positive for !1 CTC (median, 5 CTCs; range, 1-56 cells) as compared with 27% (23/84; range, 1-300 cells) using the FDAcleared CellSearch system. Furthermore, we could show that treatment response during therapy was associated with significant decreases in CTC counts (P ¼ 0.001). By dPCR, mutations in the KRAS and EGFR genes relevant for treatment decisions could be detected in CTCs captured by in vivo isolation and confirmed in the primary tumors of the same patients.Conclusions: In vivo isolation of CTCs overcomes blood volume limitations of other approaches, which might help to implement CTC-based "liquid biopsies" into clinical decision making.

show abstract

Section: Discussionsupporting

confidence: 68%

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells

Gorges

Penkalla²,

Schalk³

et al. 2016

Clinical Cancer Research

138

136

View full text Add to dashboard Cite

show abstract

“…Previous studies showed that CTCs can be frequently detected in peripheral blood of advanced CRC patients [24, 25]. CTC assessment is considered to be a relative noninvasive and sensitive monitoring technique [26].…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH)

Zhang²,

Xian

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Circulating tumor cells (CTC) are useful in early detection of colorectal cancer. This study described a newly developed platform, integrated subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH), to assess CTCs in colorectal cancer. CTCs were detected by SE-iFISH in 40 of 44 preoperative colorectal cancer patients, and yielded a sensitivity of 90.9%, which was significantly higher than CellSearch system (90.9% vs. 43.2%, P=0.033). No significant association was found between tumor stage, survival and preoperative CTC number. CTCs were detected in 10 colorectal cancer patients one week after surgery; seven patients with decreased CTC numbers (compared with preoperative CTC number) were free of recurrence; whereas two of the three patients with increased CTC numbers had tumor recurrence. Moreover, CTCs were detected in 34 colorectal cancer patients three months after surgery; patients with CTC<2 at three months after surgery had significantly longer Progression Free Survival than those with CTC>=2 (P=0.019); patients with decreased CTC number (compared with preoperative CTC number) had significantly longer Progression Free Survival than those with increased CTC number (P=0.003). In conclusion, CTCs could be detected in various stages of colorectal cancer using SE-iFISH. Dynamic monitoring of CTC numbers could predict recurrence and prognosis.

show abstract

“…In their research of lung cancer, Punnoose et al11 found that higher baseline CTC levels and decreased CTC levels upon treatment were associated with the response assessed by the Response Evaluation Criteria in Solid Tumors and longer progression-free survival. CTC levels are also regarded as a prognostic marker of metastatic prostate, breast, and colorectal cancer 12,29,30. Although the above studies indicate that CTCs can be used as a prognostic factor, Hanssen et al17 had emphasized the significance of analyzing the subpopulations of CTCs.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response

Sun¹,

Xu²,

Lian³

et al. 2017

OTT

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) possess profound influence on tumor metastases and disease progression. This study aimed to investigate the correlation of CTCs with clinical characteristics and T-cell immunity, and to explore whether CTCs and the subpopulations can serve as an independent prognostic factor in advanced non-small cell lung cancer (NSCLC). A prospective study was conducted in late stages of NSCLC patients. The levels of overall CTCs and the three subpopulation CTCs were enumerated using the CanPatrol™ CTC enrichment system. The information about the patients which included the clinical characteristics, survival status at the 200th day postdiagnosis, and the levels of T cells was collected. Mann–Whitney U test, Kruskal–Wallis H test, Cox regression, and Spearman’s rank correlation coefficient were the statistical methods used in this study. We detected CTCs in 27 of the 31 eligible patients; the level of epithelial–mesenchymal circulating tumor cells (EMCTCs) was higher than that of epithelial circulating tumor cells and that of mesenchymal circulating tumor cells (MCTCs) in the majority of NSCLC patients. Organ metastases were positively associated with the levels of overall CTCs, EMCTCs, and MCTCs (P<0.05). EMCTCs and MCTCs were associated with worse clinical outcomes. Additionally, the levels of EMCTCs were negatively associated with the levels of CD3+ T cells (P=0.01) and CD8+ T cells (P=0.04). In conclusion, the levels of CTCs were positively associated with organ metastases, particularly bone metastases, but were negatively associated with T-cell levels. The levels of EMCTCs and MCTCs had negative prognostic value.

show abstract

Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer

Cited by 47 publications

References 45 publications

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells

Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH)

Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response

Contact Info

Product

Resources

About